trial

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCTId NCT04659161
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 252 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2022-05-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
252 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2020-12-16
Primary completion
2022-05-24
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Investigators

1
Inder Kaul, MDStudy Director

Sites

22 total
Little Rock, United StatesBellflower, United StatesCulver City, United StatesGlendale, United StatesLemon Grove, United StatesLong Beach, United StatesMontclair, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United StatesSherman Oaks, United StatesMiami Lakes, United States

Linked catalysts

1
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized — primary completion2022-05-24

Facts & assertions

4 sourced
Enrollment
252
Phase
PHASE3
Primary Completion Date
2022-05-24
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia; Psychosis
indication
Schizophrenia
indication
investigator
Inder Kaul, MD
person